Sanofi Shares Plunge 9% Following Disappointing Eczema Drug Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Source: TipRanks
Sanofi's Eczema Treatment Trial Results: Sanofi's late-stage trial for its eczema treatment, amlitelimab, met its goals but disappointed investors, showing lower efficacy compared to expectations and rival drugs like Dupixent.
Market Implications and Analyst Reactions: Analysts expressed concerns over the drug's performance, with Jefferies noting it fell short of earlier trials, while Sanofi still anticipates significant sales potential, estimating over $5 billion in peak sales.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
